This paper studies the effectiveness and safety of ruxolitinib cream, a new treatment for atopic dermatitis that works by blocking certain inflammatory signals in the body. The study compared different strengths of ruxolitinib cream against a placebo cream and a standard steroid cream (triamcinolone).

This was an 8-week study where 307 patients were randomly assigned to use different treatments: various strengths of ruxolitinib cream (applied once or twice daily), a placebo cream, or triamcinolone cream. After the initial 8 weeks, patients could use the strongest ruxolitinib cream (1.5% twice daily) for 4 more weeks. The researchers measured improvements in eczema severity and itch.

The study included adult patients with mild to moderate atopic dermatitis, who had 3% to 20% of their body affected by the condition. All participants were adults, but specific age ranges were not provided in the abstract.

All strengths of ruxolitinib cream showed improvement in eczema symptoms after 4 weeks, with the strongest version (1.5% twice daily) showing the best results - 71.6% improvement compared to 15.5% with placebo. Itch relief began within 36 hours of starting treatment and lasted through the 12-week study period. The treatment was well-tolerated with no significant skin reactions where applied.

The authors concluded that ruxolitinib cream provided fast and long-lasting improvements in atopic dermatitis symptoms and was safe to use. The cream effectively reduced both eczema severity and itch.